Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Doxycycline in Relapsed NHL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed aggressive or indolent NHL following any prior treatment of the following etiologies:~  * Diffuse large B cell lymphoma (DLBCL)~ * Mantle cell lymphoma (MCL)~ * Follicular lymphoma (FL)~ * Marginal zone lymphoma (MZL)~ * Lymphoplasmacytic lymphoma (LPL)~ * Waldenstrom's macroglobulinemia (WM)~ * Small lymphocytic lymphoma (SLL)~ * Chronic lymphocytic leukemia (CLL)~ * T cell lymphoma (TCL)~* Ages ≥ 18~* Karnofsky Performance Status (KPS) ≥ 60% or Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤2~* Life expectancy of at least 3 months~* Measurable disease in at least one target lesion, assessable by radiographic examination with Fludeoxyglucose-Positron Emission Tomography (FDG-PET) or computed tomography (CT), bone marrow evaluation showing involvement, or peripheral blood showing involvement of lymphoma~* Adequate organ function:~  * Absolute neutrophil count (ANC) \> 500 cells/mL and platelet count \> 50,000 cells/mL unless felt to be secondary to lymphoma at which any count is permissible.~ * Adequate renal function as determined by Creatinine (Cr) \< 1.5x upper limit of normal (ULN) or estimated creatinine clearance of ≥ 60mL/min~ * Adequate hepatic function as determined by total bilirubin \< 1.5x upper limit of normal (ULN) (unless known Gilbert syndrome), alanine aminotransferase (ALT)and aspartate aminotransferase (AST) \< 2.5x upper limit of normal (ULN)~Exclusion Criteria:~* Known sensitivity or allergy to tetracyclines~* Lack of measurable disease by computed tomography (CT) or Fludeoxyglucose-Positron Emission Tomography (FDG-PET)~* Karnofsky Performance Status (KPS) \<60% or Eastern Cooperative Oncology Group Performance Status (ECOG PS) \>2~* Curative treatment is indicated or possible~* Inadequate organ function as measured by not fulfilling above criteria~* Pregnancy, positive serum human chorionic gonadotropin (hCG) within 28 days of enrollment, or breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Doxycycline (Type: EXPERIMENTAL): Doxycycline 200 mg twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).